Article Text

other Versions

Neonatal drug trials: impact of EU and US paediatric regulations
  1. Claudia Pansieri1,2,
  2. Maurizio Bonati2,
  3. Imti Choonara3,
  4. Evelyne Jacqz-Aigrain1,4,5
  1. 1Service de Pharmacologie Pédiatrique, AP-HP, Hôpital Robert Debré, Paris, France
  2. 2Laboratory for Mother and Child Health, Department of Public Health, IRCCS Istituto di Ricerche Farmacologiche ‘Mario Negri’, Milan, Italy
  3. 3Academic Division of Child Health, Derbyshire Children's Hospital, University of Nottingham, Derby, UK
  4. 4Université Paris Diderot, Sorbonne Paris Cité, Paris, France
  5. 5INSERM, CIC1426, Hôpital Robert Debré, Paris, France
  1. Correspondence to Professor Evelyne Jacqz-Aigrain, Department of Paediatric Pharmacology and Pharmacogénétics, Hôpital Robert Debré, 48 boulevard Serurier, Paris 75019, France; evelyne.jacqz-aigrain{at}

Statistics from

The rational use of medicines in neonates is limited by the lack of scientific evidence for their use, as most medicines used in neonates are either unlicensed or off-label.1 In order to improve this situation, legislation has been passed in Europe and the USA to encourage the pharmaceutical industry to study medicines in the paediatric and neonatal populations. In order to evaluate the impact of these paediatric regulations in the neonatal population, we analysed the drug trials registered in the database.

Among all (138 948) trials registered, 30 912 (22%) were paediatric trials, and only 288 (0.2%) involved neonates. The number of trials registered grew steadily over time. From 1999 to 2012 trials …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.